Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT)
glp1 · New England Journal of Medicine · 2023
Semaglutide 2.4mg cut major cardiovascular events by 20% in overweight/obese adults without diabetes over ~40 months.
Authors
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
Research lens
Semaglutide 2.4mg cut major cardiovascular events by 20% in overweight/obese adults without diabetes over ~40 months.
- glp1
- cardiovascular
- semaglutide
- weight-loss
- prevention